TMC125-C206: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.

This study has been completed.

Sponsor:

Information provided by:

Tibotec Pharmaceuticals, Ireland

ClinicalTrials.gov Identifier:

NCT00254046

First received: November 10, 2005

Last updated: June 2, 2011

Last verified: June 2011

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study has been completed.
Study Completion Date:	July 2008
Primary Completion Date:	February 2007 (Final data collection date for primary outcome measure)